🔗 Share this article

An underground economy for unapproved slimming drugs is propelled by social media fitness personalities and sellers on messaging platforms, according to new investigations.

Investigational Treatment Gaining Traction Via Social Media

Retatrutide, which is still in clinical trials, is being promoted by online personalities for its supposed fat-burning effects. Viewers are encouraged to message these profiles privately for source information, while also receiving promotional offers.

Thriving Trade on Social Networks

Additionally, a flourishing trade exists on Telegram, where groups with thousands of members share “before and after” images, administration instructions and assertions of rapid British shipping. Vendors promote the drug there before directing customers to WhatsApp for purchases.

Understanding The Experimental Drug

Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist patients reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed online as the successor to Ozempic.

Medical Experts Express Concerns

Nevertheless, physicians and chemists have cautions that the distribution of what is still an unlicensed drug in the UK is a cause for concern and could lead to users administering substances of unknown origin.

Several experts stated the popularity for the experimental drug could be connected to the increasing price of licensed slimming treatments such as Mounjaro.

Regulatory Position and Enforcement

Marketing the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unapproved medication that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some influencers try to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but advertising and supply can still breach medicines, advertising, and customer regulations, potentially leading to fines, legal action or prison.

Service Response and Material Removal

Based on the social media company, the service has taken down violative material and prohibited associated hashtags and query recommendations. The company stated it was dedicated to keeping the service secure and investing in strengthening enforcement strategies.

Online Marketplace Activities

Research also found communities with up to nine thousand members marketing retatrutide using the platform's integrated search feature, which functions like a public directory. Entering “retatrutide” immediately displays channels with numerous of members, filled with photos of weight loss, positive testimonials and step-by-step guides for mixing or administering at home.

After moments of joining one group, a seller posted contact information, where most purchases take place. The vendor provided an instruction manual and guaranteed delivery within 48 hours. When asked whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None inquired about weight, medical conditions or past usage.

Product Details and Costs

Inside these communities, posts show black plastic parcels with Royal Mail stickers, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, mixed at home with purified liquid, or pre-filled pens typically priced at 160 pounds for 20mg. When questioned how much time a pen should be used, vendors give conflicting responses ranging from a few weeks to “depends on your body”.

Service Oversight and Security Actions

A spokesperson for the messaging service said it regularly moderated dangerous material on its service including material that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“People are injecting materials they cannot confirm. Although the science behind retatrutide is sound, these digital products may not contain what they advertise,” stated Jason Murphy, the director of pharmacy at a pharmacy service.

A medical professional of Asda Online Doctor linked the increase in demand to recent price rises for approved slimming drugs such as Mounjaro. “With costs increasing, patients are turning to social media. But counterfeit injections are highly risky. You cannot know what’s inside or whether the environment they were made in was clean,” she said.

Her team has previously encountered patients harmed by self-injection from unconfirmed sources. “We understand the disappointment, but purchasing from messaging apps or communication platforms is taking chances with your health,” said the doctor. “These substances could be contaminated or improperly measured.”

Producer Position

A representative from Eli Lilly stated retatrutide was in third stage research studies and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this point no one can sell [it] for personal consumption,” they said, adding that any item “misleadingly claiming itself as a company experimental product not yet authorized … may subject users to potentially significant health risks”.